Related references
Note: Only part of the references are listed.A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
Fekade B. Sime et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies
Nieves Carbonell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
Luzelena Caro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy
Soo Min Jang et al.
CRITICAL CARE MEDICINE (2019)
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
Matteo Bassetti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: Lessons learned from an ancillary study of the IVOIRE trial
Dominique Breilh et al.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE (2019)
Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration
Gerardo Aguilar et al.
CRITICAL CARE (2019)
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
What a clinician should know about a renal replacement membrane?
Patrick M. Honore et al.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE (2018)
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art
Alberto Enrico Maraolo et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2017)
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L
Senthil Natesan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review
Samuel Deshayes et al.
DRUG SAFETY (2017)
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa
Jose M. Munita et al.
CLINICAL INFECTIOUS DISEASES (2017)
Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy
Weerachai Chaijamorn et al.
BLOOD PURIFICATION (2017)
Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration
Wesley D. Oliver et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration
Joseph L. Kuti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
n Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy
Derek N. Bremmer et al.
PHARMACOTHERAPY (2016)
To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt
Wai-Tat Wong et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?
Janattul-Ain Jamal et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
Seizures as adverse events of antibiotic drugs A systematic review
Raoul Sutter et al.
NEUROLOGY (2015)
A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics
Darren M. Roberts et al.
CRITICAL CARE (2015)
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A. Roberts et al.
LANCET INFECTIOUS DISEASES (2014)
Antibiotic Dosing in Critically Ill Patients Receiving CRRT: Underdosing is Overprevalent
Susan J. Lewis et al.
SEMINARS IN DIALYSIS (2014)
Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
Benjamin Miller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients
Jason A. Roberts et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Jean-Louis Vincent et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock - does the dose matter?
Federico Pea et al.
CRITICAL CARE (2009)
Acute renal failure in critically ill patients - A multinational, multicenter study
S Uchino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Share Paper
